Study: Gadolinium Contrast Agent Linked to NSF in Dialysis Patients

A new study in the October 2007 issue of Arthritis & Rheumatism finds that dialysis patients who undergo MRIs using a Gadolinium-based contrast agent have more than a 10-fold risk of developing Nephrogenic Systemic Fibrosis (NSF), a debilitating skin condition that tightens and swells the skin and may affect internal organs such as the lungs and heart. The study involved an analysis of 186 dialysis patients who had completed imaging studies with the gadolinium dye.

Additionally, the researchers found that for patients with renal failure who had NSF, the risk of dying within two years was three times greater than for those without the condition from the same dialysis center, reported Medpage Today.

The Food and Drug Administration recently added a stringent warning to all gadolinium-based products that are used for MRIs.

The so-called black box warning notes that the gadolinium agents increase the risk for NSF in patients with severe kidney disease.

If you have developed Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy following an MRI/MRA, you deserve the guidance of a lawyer experienced in such cases. Please complete the form below for a free legal evaluation.

Click To Talk To Us Online

MRI Dye Study

Journal Study: Gadolinium MRI Dye May Activate Enzyme and Cause NSF
Journal study cites Gadolinium MRI Dye as catalyst for causing NSF/NFD

NSF Study

Study: Gadolinium Contrast Agent Linked to NSF in Dialysis Patients
Patients Who Have MRI with Gadolinium Contrast Agent Have 10-fold Risk

MRI Facts

Learn MRI facts from a Gadolinium attorney and know the dangers
Information on MRIs from Gadolinium attorneys - How harmful is the dye

Name

Phone

strictly confidential

Your Question

Have you had an MRI or MRA with a contrast dye?
Do you have a prior history of kidney disease?
Were you diagnosed with Nephrongenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD)
Name
Email Address
Phone Number